Active, not recruitingPhase 3NCT06046820
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
Studying Autosomal recessive hypophosphatemic rickets
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Inozyme Pharma
- Principal Investigator
- Kurt Gunter, MDInozyme Pharma, Inc.
- Intervention
- INZ-701(drug)
- Enrollment
- 27 enrolled
- Eligibility
- 1-12 years · All sexes
- Timeline
- 2023 – 2026
Study locations (15)
- Children's Hospital of Colorado, Aurora, Colorado, United States
- Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Cook Children's Medical Center, Fort Worth, Texas, United States
- Queensland Children's Hospital, South Brisbane, Australia
- Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal, Canada
- Hôpital Bicêtre, Service d'endocrinologie et diabète de l'enfant (Childhood Endocrinology and Diabetes Department), Le Kremlin-Bicêtre, France
- King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
- Hospital San Joan de Deu, Barcelona, Spain
- Umraniye Training and Research Hospital, Istanbul, Turkey (Türkiye)
- Cukurova Universitesi Tip Fakultesi, Sarıçam, Turkey (Türkiye)
- Al Jalila Children's Specialty Hospital, Dubai, United Arab Emirates
- Royal Manchester Children's Hospital, Manchester, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06046820 on ClinicalTrials.govOther trials for Autosomal recessive hypophosphatemic rickets
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07473973ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 DeficiencyInozyme Pharma
- RECRUITINGPHASE1NCT05734196The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 DeficiencyInozyme Pharma
See all trials for Autosomal recessive hypophosphatemic rickets →